File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*
  • Basic View
  • Metadata View
  • XML View
TitleIntermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*
 
AuthorsHa, SY1
Mok, ASP1
Chu, WCW2
Rasalkar, DD2
Cheuk, DKL1
Chiang, AKS1
Ho, MHK1
Chan, GCF1
 
KeywordsCardiac magnetic resonance imaging T2* (MRI T2*)
Chelation protocol
Combined therapy
Deferiprone (L1)
Deferoxamine(DFO)
Serum ferritin(SF)
Thalassemia
 
Issue Date2011
 
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03630269.asp
 
CitationHemoglobin, 2011, v. 35 n. 3, p. 199-205 [How to Cite?]
DOI: http://dx.doi.org/10.3109/03630269.2011.579007
 
AbstractA standardized chelation protocol was applied by stratifying transfusion-dependent thalassemic patients into three groups, namely well chelated group (A), inadequately chelated group without (B) or with (C) risk of cardiac complications based on serum ferritin (SF) levels and magnetic resonance imaging (MRI) cardiac T2* measurements. Group A patients were advised to continue with deferoxamine (DFO) (Regimen Ic). Group B patients were given options of either intensification of DFO alone (Regimen Ii), deferiprone (L1) alone (Regimen II) or combined therapy with L1 and DFO (Regimen III). Group C patients were advised to take either Regimen Ii or Regimen III. The 1-year result showed that the combined therapy (Regimen III) significantly reduced SF level, cardiac and liver iron in the groups of inadequately chelated patients. The same set of outcome parameters was repeated at 2.5 years of treatment so as to evaluate the intermediate-term effects of this risk stratified chelation protocol. The number of patients with cardiac T2* <20 ms decreased from 34 (60%) at baseline to 17 (30%) of the whole cohort of 57 patients at the end of the study. There were further improvements in SF, cardiac and liver T2* in Group C patients. Significant improvement in left ventricular ejection fraction (LVEF) was demonstrated after 2.5 years of the combined therapy group in which the change was not initially apparent after the first year of assessment. Copyright © Informa Healthcare USA, Inc.
 
ISSN0363-0269
2012 Impact Factor: 0.894
2012 SCImago Journal Rankings: 0.428
 
DOIhttp://dx.doi.org/10.3109/03630269.2011.579007
 
ISI Accession Number IDWOS:000290797500003
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorHa, SY
 
dc.contributor.authorMok, ASP
 
dc.contributor.authorChu, WCW
 
dc.contributor.authorRasalkar, DD
 
dc.contributor.authorCheuk, DKL
 
dc.contributor.authorChiang, AKS
 
dc.contributor.authorHo, MHK
 
dc.contributor.authorChan, GCF
 
dc.date.accessioned2011-07-27T01:33:40Z
 
dc.date.available2011-07-27T01:33:40Z
 
dc.date.issued2011
 
dc.description.abstractA standardized chelation protocol was applied by stratifying transfusion-dependent thalassemic patients into three groups, namely well chelated group (A), inadequately chelated group without (B) or with (C) risk of cardiac complications based on serum ferritin (SF) levels and magnetic resonance imaging (MRI) cardiac T2* measurements. Group A patients were advised to continue with deferoxamine (DFO) (Regimen Ic). Group B patients were given options of either intensification of DFO alone (Regimen Ii), deferiprone (L1) alone (Regimen II) or combined therapy with L1 and DFO (Regimen III). Group C patients were advised to take either Regimen Ii or Regimen III. The 1-year result showed that the combined therapy (Regimen III) significantly reduced SF level, cardiac and liver iron in the groups of inadequately chelated patients. The same set of outcome parameters was repeated at 2.5 years of treatment so as to evaluate the intermediate-term effects of this risk stratified chelation protocol. The number of patients with cardiac T2* <20 ms decreased from 34 (60%) at baseline to 17 (30%) of the whole cohort of 57 patients at the end of the study. There were further improvements in SF, cardiac and liver T2* in Group C patients. Significant improvement in left ventricular ejection fraction (LVEF) was demonstrated after 2.5 years of the combined therapy group in which the change was not initially apparent after the first year of assessment. Copyright © Informa Healthcare USA, Inc.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationHemoglobin, 2011, v. 35 n. 3, p. 199-205 [How to Cite?]
DOI: http://dx.doi.org/10.3109/03630269.2011.579007
 
dc.identifier.doihttp://dx.doi.org/10.3109/03630269.2011.579007
 
dc.identifier.epage205
 
dc.identifier.hkuros186807
 
dc.identifier.isiWOS:000290797500003
 
dc.identifier.issn0363-0269
2012 Impact Factor: 0.894
2012 SCImago Journal Rankings: 0.428
 
dc.identifier.issue3
 
dc.identifier.pmid21599432
 
dc.identifier.scopuseid_2-s2.0-79957467894
 
dc.identifier.spage199
 
dc.identifier.urihttp://hdl.handle.net/10722/135331
 
dc.identifier.volume35
 
dc.languageeng
 
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03630269.asp
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofHemoglobin
 
dc.relation.referencesReferences in Scopus
 
dc.rightsHemoglobin. Copyright © Informa Healthcare.
 
dc.subject.meshChelation Therapy - methods
 
dc.subject.meshHeart Diseases - diagnosis - etiology - prevention and control
 
dc.subject.meshIron Chelating Agents - therapeutic use
 
dc.subject.meshMagnetic Resonance Imaging - methods
 
dc.subject.meshbeta-Thalassemia - complications - drug therapy
 
dc.subjectCardiac magnetic resonance imaging T2* (MRI T2*)
 
dc.subjectChelation protocol
 
dc.subjectCombined therapy
 
dc.subjectDeferiprone (L1)
 
dc.subjectDeferoxamine(DFO)
 
dc.subjectSerum ferritin(SF)
 
dc.subjectThalassemia
 
dc.titleIntermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Ha, SY</contributor.author>
<contributor.author>Mok, ASP</contributor.author>
<contributor.author>Chu, WCW</contributor.author>
<contributor.author>Rasalkar, DD</contributor.author>
<contributor.author>Cheuk, DKL</contributor.author>
<contributor.author>Chiang, AKS</contributor.author>
<contributor.author>Ho, MHK</contributor.author>
<contributor.author>Chan, GCF</contributor.author>
<date.accessioned>2011-07-27T01:33:40Z</date.accessioned>
<date.available>2011-07-27T01:33:40Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>Hemoglobin, 2011, v. 35 n. 3, p. 199-205</identifier.citation>
<identifier.issn>0363-0269</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/135331</identifier.uri>
<description.abstract>A standardized chelation protocol was applied by stratifying transfusion-dependent thalassemic patients into three groups, namely well chelated group (A), inadequately chelated group without (B) or with (C) risk of cardiac complications based on serum ferritin (SF) levels and magnetic resonance imaging (MRI) cardiac T2* measurements. Group A patients were advised to continue with deferoxamine (DFO) (Regimen Ic). Group B patients were given options of either intensification of DFO alone (Regimen Ii), deferiprone (L1) alone (Regimen II) or combined therapy with L1 and DFO (Regimen III). Group C patients were advised to take either Regimen Ii or Regimen III. The 1-year result showed that the combined therapy (Regimen III) significantly reduced SF level, cardiac and liver iron in the groups of inadequately chelated patients. The same set of outcome parameters was repeated at 2.5 years of treatment so as to evaluate the intermediate-term effects of this risk stratified chelation protocol. The number of patients with cardiac T2* &lt;20 ms decreased from 34 (60%) at baseline to 17 (30%) of the whole cohort of 57 patients at the end of the study. There were further improvements in SF, cardiac and liver T2* in Group C patients. Significant improvement in left ventricular ejection fraction (LVEF) was demonstrated after 2.5 years of the combined therapy group in which the change was not initially apparent after the first year of assessment. Copyright &#169; Informa Healthcare USA, Inc.</description.abstract>
<language>eng</language>
<publisher>Informa Healthcare. The Journal&apos;s web site is located at http://www.tandf.co.uk/journals/titles/03630269.asp</publisher>
<relation.ispartof>Hemoglobin</relation.ispartof>
<rights>Hemoglobin. Copyright &#169; Informa Healthcare.</rights>
<subject>Cardiac magnetic resonance imaging T2* (MRI T2*)</subject>
<subject>Chelation protocol</subject>
<subject>Combined therapy</subject>
<subject>Deferiprone (L1)</subject>
<subject>Deferoxamine(DFO)</subject>
<subject>Serum ferritin(SF)</subject>
<subject>Thalassemia</subject>
<subject.mesh>Chelation Therapy - methods</subject.mesh>
<subject.mesh>Heart Diseases - diagnosis - etiology - prevention and control</subject.mesh>
<subject.mesh>Iron Chelating Agents - therapeutic use</subject.mesh>
<subject.mesh>Magnetic Resonance Imaging - methods</subject.mesh>
<subject.mesh>beta-Thalassemia - complications - drug therapy</subject.mesh>
<title>Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*</title>
<type>Conference_Paper</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.3109/03630269.2011.579007</identifier.doi>
<identifier.pmid>21599432</identifier.pmid>
<identifier.scopus>eid_2-s2.0-79957467894</identifier.scopus>
<identifier.hkuros>186807</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-79957467894&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>35</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>199</identifier.spage>
<identifier.epage>205</identifier.epage>
<identifier.isi>WOS:000290797500003</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Prince of Wales Hospital Hong Kong